The safety and tolerability of botulinum toxins for the treatment of cervical dystonia

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX® and Dysport®) and one form of type B toxin (MyoBloc®) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain and movement of cervical dystonia. The dosing and side effects vary between the toxins. The potential availability of several forms of toxin will allow physicians to offer further treatment options to patients with CD. However, it is incumbent on the treating physicians to have a working knowledge of the different serotypes, different doses used of each formulation of each serotype, the side effect profile of each product and the potential for antibody formation for each form of toxin.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalExpert Opinion on Drug Safety
Volume4
Issue number2
DOIs
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Torticollis
Botulinum Toxins
Safety
Physicians
Therapeutics
Antibody Formation
Quality of Life
Pain
Serogroup

Keywords

  • Botulinum toxins
  • Cervical dystonia
  • Clinical trials

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. / Brashear, Allison.

In: Expert Opinion on Drug Safety, Vol. 4, No. 2, 01.03.2005, p. 241-249.

Research output: Contribution to journalReview article

@article{4b56a46d109b44c0bc5047e7b7d838d9,
title = "The safety and tolerability of botulinum toxins for the treatment of cervical dystonia",
abstract = "The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX{\circledR} and Dysport{\circledR}) and one form of type B toxin (MyoBloc{\circledR}) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain and movement of cervical dystonia. The dosing and side effects vary between the toxins. The potential availability of several forms of toxin will allow physicians to offer further treatment options to patients with CD. However, it is incumbent on the treating physicians to have a working knowledge of the different serotypes, different doses used of each formulation of each serotype, the side effect profile of each product and the potential for antibody formation for each form of toxin.",
keywords = "Botulinum toxins, Cervical dystonia, Clinical trials",
author = "Allison Brashear",
year = "2005",
month = "3",
day = "1",
doi = "10.1517/14740338.4.2.241",
language = "English (US)",
volume = "4",
pages = "241--249",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The safety and tolerability of botulinum toxins for the treatment of cervical dystonia

AU - Brashear, Allison

PY - 2005/3/1

Y1 - 2005/3/1

N2 - The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX® and Dysport®) and one form of type B toxin (MyoBloc®) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain and movement of cervical dystonia. The dosing and side effects vary between the toxins. The potential availability of several forms of toxin will allow physicians to offer further treatment options to patients with CD. However, it is incumbent on the treating physicians to have a working knowledge of the different serotypes, different doses used of each formulation of each serotype, the side effect profile of each product and the potential for antibody formation for each form of toxin.

AB - The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX® and Dysport®) and one form of type B toxin (MyoBloc®) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain and movement of cervical dystonia. The dosing and side effects vary between the toxins. The potential availability of several forms of toxin will allow physicians to offer further treatment options to patients with CD. However, it is incumbent on the treating physicians to have a working knowledge of the different serotypes, different doses used of each formulation of each serotype, the side effect profile of each product and the potential for antibody formation for each form of toxin.

KW - Botulinum toxins

KW - Cervical dystonia

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=20944450705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944450705&partnerID=8YFLogxK

U2 - 10.1517/14740338.4.2.241

DO - 10.1517/14740338.4.2.241

M3 - Review article

C2 - 15794717

AN - SCOPUS:20944450705

VL - 4

SP - 241

EP - 249

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -